Literature DB >> 23867985

I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.

Lauretta Maggi1, Giovanna Bruni, Mariarosa Maietta, Andrea Canobbio, Andrea Cardini, Ubaldo Conte.   

Abstract

Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. The main problem in formulating an oral dosage form is its low solubility in aqueous media. This problem is particularly critical for an anti-diabetic drug because it should be administered just before the meals and be quickly bioavailable to cover the post-prandial glycemic peak. In this work, some technological approaches have been studied to improve the dissolution rate of nateglinide. Furthermore, two different polymorphs of nateglinide (H and B) have been tested to evaluate the influence of the crystal habitus on the dissolution behavior of the drug. The results have clearly demonstrated that wettability plays a key role in the dissolution behavior of nateglinide. As a matter of fact the physical dispersion of the drug with colloidal silica or hydrophilic swellable polymers strongly enhances the dissolution rate of nateglinide. The two polymorphs tested did not show significant differences in terms of dissolution behavior.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-mixing, silica; Dissolution rate; Hydrophilic swellable polymers; Insoluble drug; Nateglinide

Mesh:

Substances:

Year:  2013        PMID: 23867985     DOI: 10.1016/j.ijpharm.2013.06.084

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  1 in total

1.  Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.

Authors:  Simon Megy; Stephanie Aguero; David Da Costa; Myriam Lamrayah; Morgane Berthet; Charlotte Primard; Bernard Verrier; Raphael Terreux
Journal:  Nanomaterials (Basel)       Date:  2020-11-05       Impact factor: 5.076

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.